Objective: Resolvins have been shown to attenuate inflammation, whereas NETosis, the process of neutrophils releasing neutrophil extracellular traps (NETs), produces increased inflammation. It is hypothesized that treatment of animals with resolvin D1 (RvD1) would reduce abdominal aortic aneurysm (AAA) formation by inhibiting NETosis.
At least 12,000 individuals die of ruptured abdominal aortic aneurysm (AAA) each year, representing a mortality rate of >70%.
1 Surveillance screening and surgical repair for AAA >5 cm has cut the mortality rate in half, 2 but there is currently no successful medical therapy. Many factors have been shown to contribute to the mechanism of AAA disease. One such pathway of recent interest has been NETosis. 3 First reported in 2004,
NETosis is the process of nuclear chromatin extracellular traps released by neutrophils (NETs) to engulf pathogens and to cause cell death in a pathway distinct from apoptosis and necrosis. 4, 5 As neutrophils are the first responders to infection, experimental evidence has shown that NETosis can both inhibit and upregulate sterile inflammation for many chronic diseases, including atherosclerosis and gout. 6, 7 Previous studies from our laboratory demonstrated that neutrophil depletion reduces aortic aneurysm diameter by 60% in mice on day 14 in the elastase perfusion model 8 and that neutrophils peak on day 3 before maximum AAA growth in the elastase perfusion model. 9 By inhibiting NETosis, which is produced by early-responding neutrophils, AAA inflammation could be decreased. Resolvin D1 (RvD1) is one of the D-series resolvins that makes up the resolvin family. Resolvins are naturally occurring lipid-derived proresolving mediators that act on the resolution phase of inflammation. 10 It has been reported that RvD1 acts closely with neutrophils to resolve inflammation. 11 Inhibiting NETosis therefore represents a possible pathway by which RvD1 could be used as a medical therapy for AAA. In this study, it is hypothesized that RvD1 resolves AAA formation by targeting and inhibiting an early neutrophil inflammatory response, NETosis.
METHODS

Animal housing
The 8-week-old wild-type C56BL/6 male mice (Jackson Laboratory, Bar Harbor, ME) were housed and maintained at 70 F, 50% humidity, in 12-hour light-dark cycles per institutional animal protocols. Mice were provided drinking water and fed either a minimal phytoestrogen diet (2017 Teklad Global 16% Protein Rodent Diet; Harlan Labs, Inc, Frederick, Md) for the elastase-induced AAA model or a high-fat diet for the angiotensin II (Ang II)-induced AAA model (D12079B; Research Diets Inc, New Brunswick, NJ). We chose male mice because clinically AAA is four times more likely to occur in men than in women and because there is a higher incidence of aortic aneurysms in male mice compared with female mice in previous AAA mouse models. [12] [13] [14] [15] [16] All experiments were conducted in accordance with the standards approved by the University of Virginia Animal Care and Use Committee (#3848).
Topical elastase surgery, treatment plan, and harvest Deactivated elastase control group (n [ 19) . Mice underwent sham AAA induction surgery, during which 5 mL of heat-deactivated (100 C for 30 minutes) elastase, instead of active elastase, was applied topically to the aorta. The rest of the surgical procedure is identical to the other two groups. Depending on the day of harvest, phosphate-buffered saline (PBS) was injected intravenously once a day from the day of the surgery (day 0) to the day of harvest (day 3 or day 14) .
Elastase group (n [ 18) . The methods for induction of anesthesia, surgical procedure for AAA formation, and postoperative analgesia have been previously described. 17 In short, after the abdominal aorta is circumferentially dissected from approximately 2 mm below the left renal vein to the bifurcation, a fine-tip pipet is then used for topical application of 5 mL of elastase (Sigma-Aldrich, St. Louis, Mo; 10.1 mg protein/mL, 19 units/mg protein) to the exposed aortic adventitia for 5 minutes. After 5 minutes, the aorta is dried with a cotton-tipped applicator, the intestines are returned to the abdominal cavity, and the laparotomy is closed in layers. Depending on the day of harvest, PBS was injected daily from the day of the surgery (day 0) to the day of harvest (day 3 or 14). RvD1 treated group (n [ 18) . The mice underwent the same AAA induction procedure as previously described. 17 Depending on the day of harvest, RvD1 (300 ng/kg in 300-mL volume solution; Cayman Chemicals, Ann Arbor, Mich) was injected daily from the day of the surgery (day 0) to the day of harvest (day 3 or day 14).
Mice from each group were euthanized under anesthesia by overdose and exsanguination. The abdominal aorta, from below the left renal vein to the bifurcation, was dissected. The external aortic adventitia diameter was measured at its maximum diameter and at the intact self-control portion just below the left renal vein using video microscopy with NIS-Elements D.3.10 software attached to the microscope (Nikon SMZ-800; Nikon Instruments, Melville, NY). 17 Aortic dilation percentage was determined using (maximal AAA diameter À self-control aortic diameter)/maximal AAA diameter Â 100%. 17 A dilation of $100% was considered to be positive for AAA. 17 On postoperative day 3 or day 14, after diameter measurement, serum and aneurysm tissue were collected for cytokine analyses (n ¼ 6/group/ day 3), gelatin zymography (n ¼ 6-9/group/day 3), Western blot (n ¼ 3-6/group/day 3), and enzyme-linked immunosorbent assay (ELISA; n ¼ 10/group/day 3). Aortic tissue was also collected for histology (n ¼ 4-5/group/day 3 and day 14).
ARTICLE HIGHLIGHTS
Ang II osmotic infusion pump surgery, treatment plan, and harvest An osmotic infusion pump (Alzet 1004; Durect Corp, Cupertino, Calif) containing 1000 ng/kg/min of Ang II was implanted subcutaneously into 20 ApoE À/À male mice (Jackson Laboratory) on a high-fat diet introduced 1 week before the day of surgery as previously described. 16, [18] [19] [20] In the Ang II control group, mice (n ¼ 28)
received PBS intravenously once a day from the day of surgery (day 0) to the day of harvest (day 3 or day 28). In the RvD1-treated group, mice (n ¼ 25 mice) received RvD1 once a day from the day of the surgery (day 0) to the day of harvest (day 3 or day 28). Mice were euthanized under anesthesia by overdose and exsanguination. The abdominal aorta was fully dissected, and video micrometry measurements of the maximum aortic diameter were performed using NIS-Elements D.3.10 software attached to the microscope (Nikon SMZ-800). On postoperative day 3 or day 28, aortic samples were then flash-frozen and used for cytokine analysis (n ¼ 9-10/group/day 28). Any mouse that died before the study end point underwent autopsy to determine cause of death. One day 3 mouse in the RvD1-treated group died during the injection process, and one day 28 mouse in the Ang II group died of aortic rupture.
Cytokine array
Using isolated protein from murine abdominal aortas, cytokine arrays (R&D Systems, Minneapolis, Minn) were completed according to the manufacturer's instructions on mice harvested on day 3 and day 28 (n ¼ 4-6/group). Protein samples from each group were pooled for analysis; all samples were run in duplicate, and the mean value was used. 21 ELISA An ELISA analysis was performed for interleukin (IL) 1b according to the manufacturer's instructions (BD Biosciences Pharmingen, San Diego, Calif). Protein samples (10 mg/well) isolated from the mouse abdominal aorta (n ¼ 10/group) were used for the IL-1b ELISA. An RvD1 ELISA kit (Cayman Chemicals) was used to measure the RvD1 levels in the elastase AAA-induced mice groups (n ¼ 4/group) according to the manufacturer's instructions.
Western blot
Citrullinated histone H3 has previously been shown to be a marker for NETosis. 22, 23 Therefore, by determining that citrullinated histone H3 levels are decreased in day 3 RvD1-treated mice, it would link treatment with RvD1 to possibly inhibiting NETosis. Wild-type mice (C57BL/6 male mice) pretreated with RvD1 were harvested on day 3 and the aortas underwent citrullinated histone 3 (anticitrullinated histone H3-citrulline 2 þ 8 þ 17 antibody; Abcam, Cambridge, Mass) protein Western blot according to the manufacturer's instructions (n ¼ 3-6/group).
Histology
Aortic tissue was fixed in 4% buffered formaldehyde for 24 hours, transferred to 70% ethanol, and embedded in paraffin. Day 3-harvested (n ¼ 4-5/group) cross sections were prepared with Verhoeff-van Gieson (VVG) for elastin 24 and immunohistochemical staining for citrullinated histone H3 (ab5103, 1:100 dilution; Abcam), noncitrullinated histone H3 (ab1791, 1:300 dilution; Abcam), neutrophils, 24 neutrophil elastase (ab21595, 1:200 dilution; Abcam), and smooth muscle a-actin. 18 For grading, the positive staining area of the entire aortic tissue sample was selected and measured using integrated optical density of each section. Day 14-harvested (n ¼ 4/group) cross sections were prepared with VVG and immunohistochemical staining for neutrophils. 24 
Gelatin zymography
Gelatin zymography was performed using isolated protein from the abdominal aortic samples (n ¼ 6-9/group) to measure pro and active matrix metalloproteinase (MMP) 2 and 9 activity. Precast zymography gels (10%; Invitrogen, Carlsbad, Calif) were loaded with 3 mg of aortic protein from each sample. Samples were diluted into tris-glycine sodium dodecyl sulfate sample buffer (2Â) and electrophoretically separated under nonreducing conditions. The gels were renatured for 30 minutes in renaturing buffer (Invitrogen) and incubated in developing buffer (Invitrogen) for 24 hours at 37 C while rocking. The gels were then stained in SimplyBlue SafeStain (Invitrogen). Pro and active forms of MMP2 and MMP9 appeared as clear bands against the blue background. Quantification was determined according to the optical density using Image Lab Software version 4.0 (Bio-Rad, Hercules, Calif).
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Statistical analysis GraphPad Prism 7 (GraphPad Software, La Jolla, Calif) software was used for all statistical analyses. AAA diameter, RvD1 ELISA, Western blot, histology, and cytokine analysis were determined using an unpaired t-test. Zymography comparisons were determined by a Mann-Whitney test. The data are presented as mean values and standard error, with an P < .05 considered statistically significant. Day 3 citrullinated histone H3 is lower in the RvD1-treated group, whereas RvD1 levels are higher in the AAA elastase group. As previously stated, determining that citrullinated histone H3 (a marker for NETosis 22, 23 ) levels are decreased in day 3 RvD1-treated mice would link RvD1 to possibly inhibiting NETosis. RvD1-treated mice harvested on day 3 had citrullinated histone H3 levels significantly lower than in the elastase group, as shown by Western blot (0.83 6 0.1 vs 1.23 6 0.1 densitometry units; P ¼ .04; Fig 2) . The deactivated elastase group also had significantly lower citrullinated histone H3 volume intensities compared with the elastase group (0.63 6 0.05 vs 1.23 6 0.1 densitometry units; P < .001; Fig 2) . The difference between the deactivated elastase and the RvD1-treated groups was not significant, showing how citrullinated histone H3 levels in the RvD1-treated group more closely resemble the Fig 1. A, Topical elastase treatment design. 1, Deactivated elastase control group. Sham abdominal aortic aneurysm (AAA) induction surgery was performed using deactivated elastase, and mice were injected with phosphate-buffered saline (PBS) once a day until harvest on day 3 or day 14. 2, Elastase group. Active elastase was used to induce AAA, and mice were injected with PBS once a day until harvest on day 3 or day 14. 3, Resolvin D1 (RvD1)-treated group. AAA was induced, and mice were injected with RvD1 (300 ng in 300-mL volume solution) once a day until harvest on day 3 or day 14. B, Day 14 topical elastase AAA model phenotype. AAA percentage dilation is decreased in the RvD1-treated group vs the elastase group (84.9% vs 136.5%; *P < .001; n ¼ 8/group). C and D, Verhoeff-van Gieson (VVG) histology images and quantification. Elastin is preserved in the RvD1-treated group. The ratios of the elastin/tissue levels in the RvD1-treated group are increased compared with the elastase group (0.028% vs 0.070%; *P ¼ .01; n ¼ 4-5/group).
RESULTS
Day
deactivated elastase group rather than the elastase group (P > .05; Fig 2) . RvD1 levels were significantly higher in elastase AAA-induced serum compared with the deactivated elastase group (183.3 6 27.5 pg/mL vs 75.5 6 14.2 pg/mL; P ¼ .01).
IL-1b is downregulated whereas IL-10 is upregulated in the RvD1-treated group. After a significant decrease in citrullinated histone H3 levels was shown with RvD1 treatment 3 days after elastase application, inflammatory cytokine levels known to be important in AAA formation were examined during AAA formation in RvD1-treated mice. The day 3 RvD1-treated mice demonstrated decreased IL-1b cytokine levels in aortic tissue by ELISA compared with the elastase group (P ¼ .02; Fig 3, A) . Decreased IL-1b levels demonstrate that RvD1 is affecting a cytokine important to aneurysm progression as early as 3 days into treatment therapy. 8, 25, 26 Another cytokine known to be important in AAA, IL-6, trended down as 23% densitometry units; *P ¼ .04; n ¼ 3/group). The deactivated elastase group is also decreased vs the elastase group (0.63% vs 1.23%; **P < .001; n ¼ 3-6/group). The RvD1-treated group shows no statistical difference from the deactivated elastase group (P > .05; n ¼ 3-6/group). well (P ¼ .18). Pooled animal aortic tissue harvested on day 3 from the RvD1-treated group also showed significantly increased levels of IL-10, a protective cytokine, through cytokine array compared with the elastase group (P ¼ .01; Fig 3, B) .
E l a s t a s e R v D 1 T r e a t e d
RvD1 treatment shows decreased staining for NETosis markers. Immunohistochemical staining at 10Â magnification (Fig 4, A) substantiated the impact of RvD1 on day 3. There was no statistical difference regarding neutrophil (polymorphonuclear) infiltration and noncitrullinated histone H3 between the RvD1-treated group and the elastase group (P < .05; Fig 4, B and C) . Confirming the previously mentioned Western blot results, there were significantly decreased levels of citrullinated histone H3 in the RvD1-treated group vs the elastase group (P ¼ .03 ;  Fig 4, D) . Neutrophil elastase staining was also significantly decreased in the RvD1-treated group compared with the elastase group (P ¼ .002 ; Fig 4, E) . In addition, the RvD1-treated group expressed significantly more elastin preservation compared with the elastase group (P ¼ .037).
Active MMP2 is downregulated in the day 3 RvD1 treatment group. After elastin protection was noted in the day 3 RvD1-treated group, gelatin zymography on day 3 was used to see whether RvD1 decreased the degradation of the extracellular matrix proteins that occur in AAA formation. Zymography demonstrated decreased active MMP2 activity in the RvD1-treated group compared with the elastase group (62,048 vs 176,859 densitometry units; P ¼ .03; Fig 5) . Active MMP2 in the deactivated elastase group was also significantly lower compared with the elastase group (P < .001). Pro-MMP2 as well as pro and active forms of MMP9 were not significantly different between the RvD1 and elastase groups (P > .05). RvD1 decreased AAA formation and citrullinated H3 in the Ang II mouse model. After RvD1 was found to lower citrullinated H3 and to attenuate AAA in the topical elastase model, a second model was needed to confirm the results. Mice treated with RvD1 showed significantly decreased abdominal aortic diameter on day 28 compared with the Ang II group in the Ang II infusion AAA model (0.97 6 0.057 mm vs 1.65 6 0.25 mm; P ¼ .016; Fig 6, A and B ). There were no significant changes in death rates due to rupture (P > .05). Cytokine array showed decreased levels of IL-1b, interferon g, C-X-C motif chemokine ligand 10 (CXCL-10), monocyte chemotactic protein 1, and regulated on activation, normal T cell expressed and secreted (RANTES) on day 28-harvested mice in RvD1-treated animals (P < .05; Fig 6, C) . RvD1-treated mice aortic tissue harvested on day 3 had citrullinated histone H3 levels significantly lower than in the Ang II group, as shown by Western blot (0.133 6 0.014 vs 0.211 6 0.005 densitometry units; P ¼ .002; Fig 7, A and B) . IL-10 levels were increased in RvD1-treated tissue of day 3-harvested mice through cytokine array (P ¼ .01; Fig 7, C) . Staining showed no significant difference in the number of neutrophils between the Ang II group and the RvD1-treated group (P ¼ .8935).
DISCUSSION
In this study, RvD1 treatment is associated with inhibition of NETosis as shown by decreased levels of citrullinated histone H3 and neutrophil elastase at early time points. Histology and ELISA results also support both RvD1's effectiveness in attenuating AAA and its link to inhibiting NETosis. In association with NETosis inhibition, RvD1 reproducibly inhibited AAA formation in two murine models, downregulating proinflammatory cytokines, upregulating anti-inflammatory cytokines, and decreasing MMP levelsdall known to be important in AAA formation.
Resolvins are also "strategically positioned" to have an impact on neutrophils because they are generated between the initiation phase and resolution phase of inflammation. 27 To show how RvD1 was mechanistically having an impact on AAA growth, it was imperative that we study earlier time points (day 3 when neutrophils peak) 9 more closely connected to neutrophil inflammatory recruitment. Neutrophils are the first inflammatory cells recruited to the site of infection 6, 28 and, when AAA is induced, 9 reach their peak 3 days after surgery. 29 Akagi et al 30 documented the connection between resolvins and neutrophils, with RvD2 reducing neutrophil infiltration by 48% and Maresin 1 (another family of resolvins) reducing neutrophil infiltration by 56% in a carotid ligation model. Immediate effects of RvD1, specifically on neutrophils, are seen using the 3-day models as RvD1 levels in the serum of elastase-treated mice are higher than in the deactivated elastase mice on day 3. This suggests that RvD1 is present during the early inflammatory period and could inhibit inflammation by affecting neutrophils. Decreased elastin breaks in the RvD1 group compared with the elastase group on day 3 also suggest that RvD1 contributes to reducing AAA formation in the early stages of aneurysm inflammation.
Resolvins have previously been shown to mitigate inflammation by decreasing macrophage 16 and smooth muscle infiltration. 31 In this paper, RvD1 inhibits AAA growth as shown in mice using the 14-day topical elastase model and the 28-day Ang II model. The decrease in interferon g, IL-1b, CXCL-10, monocyte chemotactic protein 1, and RANTES cytokines in the RvD1-treated 28-day group and the decrease of elastin breaks in the RvD1-treated 14-day group further demonstrate RvD1's effectiveness in attenuating AAA. The early effects of RvD1 were shown in a significant decrease in the proinflammatory cytokines IL-1b and IL-6 on day 3 also, which when lowered have been shown to prevent aortic aneurysm formation. 25, 32 These cytokines are also increased in other diseases in which NETosis is thought to be a key player, like gout. 33 Paradoxically, the anti-inflammatory cytokine IL-10 level increased in the day 3 RvD1-treated group in both the elastase and Ang II AAA model. This suggests that resolvins fight inflammation by increasing the amount of the anti-inflammatory cytokines 21 as well as decreasing proinflammatory cytokines. In addition, decreased active MMP2 on day 3 further links RvD1 to a common AAA inflammatory process, but more investigation is needed to explain how inhibiting NETosis can affect the mechanism of MMP2 and MMP9 activity. Mechanistically, decreased levels of citrullinated histone H3 in RvD1-treated mice using Western blot and immunohistochemical staining offer a possible mechanism as to how RvD1 is lowering inflammation by acting on neutrophils. Citrullination is the process of deamination that charges the amino acid arginine into the uncharged side chain, citrulline. 6 Because H3 citrullination is associated with rapid intracellular decondensation of nuclear chromatin 6 and inhibiting citrullination has been shown to lower NET formation, 34 citrullinated histone H3 has been linked in humans and mice as a marker for NETosis. 7, 22, 23 This study reveals that RvD1 is possibly inhibiting NETosis through lowering of citrullination.
To make sure that RvD1 is not affecting total histone levels and instead is specific toward NETs, noncitrullinated H3 was also stained. Because the noncitrullinated histone H3 is not significantly different in the RvD1 group vs the elastase group, it is hypothesized that the RvD1 is Fig 6. A, Angiotensin II (Ang II) treatment design. 1, Ang II control group. Ang II was delivered by subcutaneous osmotic pumps, and mice were injected with phosphate-buffered saline (PBS) once a day until harvest on day 3 or day 28. 2, Resolvin D1 (RvD1)-treated group. Ang II was delivered by subcutaneous osmotic pumps, and mice were injected with RvD1 once a day until harvest on day 3 or day 28. B, Day 28 Ang II abdominal aortic aneurysm (AAA) model phenotype. AAA maximum diameter is decreased in the RvD1-treated group vs the Ang II group (0.97 mm vs 1.65 mm; *P ¼ .016; n¼ 12-13/group). C, Day 28 cytokine array results. Day 28 interleukin 1b (IL-1b), interferon g (INF-g), C-X-C motif chemokine ligand 10 (CXCL-10), monocyte chemotactic protein 1 (MCP-1), and regulated on activation, normal T cell expressed and secreted (RANTES) cytokine levels are downregulated in the RvD1-treated group compared with the Ang II group (all *P < .05; n ¼ 4-5 pooled/group). not generally decreasing the infiltration of neutrophils but more specifically targeting the process of NETosis. The lower level of neutrophil elastase staining in the RvD1-treated group vs the elastase group also implies the specificity of RvD1 to NETs, 3 as does the nonsignificant difference of neutrophil infiltration at day 3 between the same groups and the nonsignificant difference in macrophage staining at day 3. The Ang II model also showed no significant differences in neutrophil depletion between the RvD1-treated group and the Ang II control group while also showing depleted levels of citrullinated H3 in the RvD1-treated group. These data, in connection with the elastase model results, further show the possibility for RvD1 to affect NETosis independently of neutrophils. More studies are needed to further link NETosis and RvD1 with AAA formation. Even though our goal was to look at the role of RvD1 on early-responding neutrophils undergoing NETosis, studies showing the ability of RvD1 to resolve established AAA would strengthen the translational power of resolvins. Using the D-series 2 resolvin, Pope et al 21 showed inhibition of AAA growth in formed AAA using a mouse model. In vitro studies showing the direct inhibition of NETosis by RvD1 could also help further confirm that resolvins might specifically target NETosis. NETosis has been shown to be triggered by lipopolysaccharides in many other types of inflammatory diseases, 35, 36 and RvD1 can protect against lipopolysaccharides. 36 It is also hypothesized that RvD1 works through formyl peptide receptor 1 (FPR2), and studies show that NETosis in humans can be inhibited by a FPR2 agonists. 37 The ligands binding to FPR2 can have both proinflammatory and proresolution effects. 38 The results of this study show the beneficial effects of resolvins in inhibiting AAA growth. Although these results highlighted just a single resolvin, resolvins have been hypothesized to act on many different pathways. 22, 28 Linking RvD1 to NETosis offers an example as to how certain resolvins might act to slow AAA growth and possibly lead to a medical treatment of earlyidentified growing AAA in the future.
CONCLUSIONS
This study demonstrates that resolvin treatment decreases AAA size. This occurs in association with the inhibition of NETosis by RvD1 as demonstrated by decreased citrullinated histone H3 and neutrophil elastase levels in two well-established AAA models. Histologic staining and cytokine profiles further support the anti-NETosis effects of RvD1. These results suggest that RvD1 could be a possible medical therapy for inhibition of AAA growth. We thank Anthony Herring, Cindy Dodson, Sheila
